Raw authenticity can be disruptive in life sciences workplaces, but learning corporate fluency and stylistic pivots can help leaders become strategically authentic, writes Hope Mueller.

Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

On episode 120 of Cell & Gene: The Podcast, Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf ...

On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...

Single-domain antibodies (sdAbs), also known as NANOBODY® molecules, offer unique advantages in research and medicine, but their purification can be challenging due to limited affinity for Protein A.

Life sciences organizations invest heavily in marketing visibility. Most maintain a website, actively use LinkedIn, and participate in industry events. These efforts signal credibility, momentum, and ...

Artificial intelligence is reshaping life sciences, but deciding whether to build or buy AI solutions can be complex. This guide explores the critical factors behind each approach, helping ...

Agentic AI is redefining how life sciences organizations approach discovery and operations. Unlike traditional AI models that simply predict outcomes, agentic systems act autonomously, making ...

The FDA has approved the first oral GLP-1 treatment for obesity in the U.S.—Novo Nordisk’s Wegovy pill. This once-daily medication represents a major advancement in weight management, offering an ...

This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and ...

Small and mid-cap biotechs face a fundamental strategic choice that will determine their survival in this new world of business. How will they compete against well-capitalized incumbents while ...

The transition from traditional inventory to order-based fulfillment represents a fundamental shift in how advanced therapies reach patients. Unlike standard pharmaceuticals, cell and gene therapies ...